跳至主要内容
临床试验/ACTRN12607000090415
ACTRN12607000090415尚未招募2 期

Phase II Trial of Temozolomide and Caelyx in the Treatment of Patients with Glioblastoma Multiforme following concurrent radiotherapy and chemotherapy to improve six month progression free survival

Schering-Plough0 个研究点目标入组 40 人开始时间: 2007年1月29日最近更新:
适应症

试验速览

阶段
2 期
状态
尚未招募
发起方
入组人数
40

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Non-randomised trial
主要目的
Treatment
盲法
Open (masking not used)

入排标准

年龄范围
18 Years 至 ot stated(—)
性别
All

入选标准

  • Inclusion: Newly diagnosed glioblastoma, performance status 0-2, completed post-operative concurrent radiotherapy/chemotherapy.

排除标准

  • Exclusion: significant co-morbidities

研究者

发起方
Schering-Plough

相似试验

进行中(未招募)
不适用
A Phase II study of Temozolomide (Temodal) Given Continously 100mg/m2 for 21 Days in 28 Day cycles in Patients with Metastatic Melanoma.Metastatic melanoma
EUCTR2004-002925-39-SEKliniken för onkologi, Karolinska Universitetssjukhuset, Solna35
进行中(未招募)
不适用
PHASE 2 SINGLE- ARM STUDIES OF TEMOZOLOMIDE IN COMBINATION WITH TOPOTECANIN REFRACTORY AND RELAPSED NEUROBLASTOMA AND OTHER PAEDIATRIC SOLID TUMOURS - TOTEM 2EUROBLASTOMA AND OTHER PAEDIATRIC SOLID TUMOURSMedDRA version: 9.1Level: PTClassification code 10029260MedDRA version: 9.1Level: PTClassification code 10039491
EUCTR2009-012644-16-ITPOLICLINICO UNIVERSITARIO AGOSTINO GEMELLI93
进行中(未招募)
不适用
Phase 2 single-arm studies of Temozolomide in combination with Topotecan in refractory or relapsing Neuroblastoma and Other pediatric solid tumours. - ITCC 013 - TOTEM2euroblastoma and Other pediatric solid tumours.MedDRA version: 9.1Level: LLTClassification code 10066595Term: Neuroblastoma recurrent
EUCTR2008-001436-12-ATInstitut Gustave Roussy93
进行中(未招募)
不适用
Phase 2 single-arm studies of Temozolomide in combination with Topotecan in refractory or relapsing Neuroblastoma and Other pediatric solid tumours. - ITCC 013 - TOTEM2euroblastoma and Other pediatric solid tumours.MedDRA version: 9.1Level: LLTClassification code 10066595Term: Neuroblastoma recurrent
EUCTR2008-001436-12-FRInstitut Gustave Roussy125
进行中(未招募)
不适用
Phase 2 single-arm studies of Temozolomide in combination with Topotecan in refractory or relapsing Neuroblastoma and Other pediatric solid tumours. - ITCC 013 - TOTEM2
EUCTR2008-001436-12-NLInstitut Gustave Roussy93